The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 09, 2021

Filed:

Apr. 29, 2019
Applicant:

Baylor Research Institute, Dallas, TX (US);

Inventors:

SangKon Oh, Baltimore, MD (US);

Sandra Zurawski, Midlothian, TX (US);

Gerard Zurawski, Midlothian, TX (US);

Assignee:

Baylor Research Institute, Dallas, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 39/395 (2006.01); C07K 14/025 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/39541 (2013.01); C07K 14/005 (2013.01); C07K 16/2878 (2013.01); C12N 7/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/585 (2013.01); A61K 2039/6056 (2013.01); A61K 2039/70 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2319/74 (2013.01); C07K 2319/91 (2013.01); C12N 2710/20034 (2013.01);
Abstract

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.


Find Patent Forward Citations

Loading…